Humanized anti-EGFL7 antibodies and methods using same
AssigneeGenentech, Inc.
InventorsWeilan Ye, Mark S. Dennis, Jill Fredrickson
Life of this patent
Estimating the term…
Abstract
The present invention concerns antibodies to EGFL7 and the uses of same.
Claims30
A method of reducing or inhibiting perfusion and permeability of a tumor which expresses EGFL7 in a subject, the method comprising administering to an individual in need of such treatment an effective amount of an anti-EGFL7 antibody, the antibody comprising a variable domain comprising the following HVR sequences:
- HVR-L1 comprising RTSQSLVHINXITYLH, wherein X is G or A (SEQ ID NO:
- 106, 241);
- HVR-L2 comprising RVSNRFS (SEQ ID NO:
- 101);
- HVR-L3 comprising GQSTHVPLT (SEQ ID NO:
- 131);
- HVR-H1 comprising GYTFIDYYMN (SEQ ID NO:
- 103);
- HVR-H2 comprising GDINLDNXGTHYNQKFKG (SEQ ID NO:
- 104, 242), wherein X is G or S;
- and
- HVR-H3 comprising AREGVYHDYDDYAMDY (SEQ ID NO:
- 105).
A method of reducing or inhibiting perfusion and permeability of a tumor which expresses EGFL7 in a subject, the method comprising administering to an individual in need of such treatment an effective amount of an anti-EGFL7 antibody, wherein the anti-EGFL7 antibody comprises the following HVR sequences:
- HVR-L1 comprises the amino acid sequence RTSQSLVHINAITYLH (SEQ ID NO:
- 241), HVR-L2 comprises the amino acid sequence RVSNRFS (SEQ ID NO:
- 101), HVR-L3 comprises the amino acid sequence GQSTHVPLT (SEQ ID NO:
- 131), HVR-H1 comprises the amino acid sequence GYTFIDYYMN (SEQ ID NO:
- 103), HVR-H2 comprises the amino acid sequence GDINLDNSGTHYNQKFKG (SEQ ID NO:
- 242), and HVR-H3 comprises the amino acid sequence AREGVYHDYDDYAMDY (SEQ ID NO:
- 105).
Dependencies are inferred from the claim text.